Novartis-partnered biotech gets $150M Series B to move into the clinic
Matchpoint Therapeutics, a biotech partnered with Novartis, has put together its latest financing round. The $150 million Series B will help fund Matchpoint’s efforts to get its lead program into human ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.